MANNKIND CORP Interest Expense Nonoperating
MANNKIND CORP (MNKD) reported Interest Expense Nonoperating of $11.89 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-05
- MANNKIND CORP interest expense nonoperating for the quarter ending 2026-06-30 was $11.89M, a 4073.33% increase year-over-year.
- MANNKIND CORP interest expense nonoperating for the quarter ending 2026-03-31 was $7.48M, a 60.99% increase year-over-year.
- MANNKIND CORP interest expense nonoperating for the quarter ending 2025-12-31 was $7.54M, a 382.46% increase year-over-year.
- MANNKIND CORP interest expense nonoperating for the quarter ending 2025-09-30 was $1.36M, a 24.26% decline year-over-year.
- MANNKIND CORP interest expense nonoperating for fiscal 2025 was $13.83M, a 15.43% increase from fiscal 2024.
- MANNKIND CORP interest expense nonoperating for fiscal 2024 was $11.98M, a 20.92% decline from fiscal 2023.
- MANNKIND CORP interest expense nonoperating for fiscal 2023 was $15.15M, a 0.93% increase from fiscal 2022.
- MANNKIND CORP interest expense nonoperating for fiscal 2022 was $15.01M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.89M 10-Q · filed 2026-08-05 | $19.37M 10-Q · filed 2026-08-05 | $26.91M derived: sum of 3 quarters · filed 2026-08-05 | $28.27M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $7.48M 10-Q · filed 2026-05-06 | $15.01M derived: sum of 2 quarters · filed 2026-05-06 | $16.38M derived: sum of 3 quarters · filed 2026-05-06 | $16.66M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $7.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.90M derived: sum of 2 quarters · filed 2026-02-26 | $9.19M derived: sum of 3 quarters · filed 2026-08-05 | $13.83M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.36M 10-Q · filed 2025-11-05 | $1.65M derived: sum of 2 quarters · filed 2026-08-05 | $6.29M 10-Q · filed 2025-11-05 | $7.86M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $285.00K 10-Q · filed 2026-08-05 | $4.93M 10-Q · filed 2026-08-05 | $6.49M derived: sum of 3 quarters · filed 2026-08-05 | $8.29M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $4.64M 10-Q · filed 2026-05-06 | $6.21M derived: sum of 2 quarters · filed 2026-05-06 | $8.01M derived: sum of 3 quarters · filed 2026-05-06 | $14.06M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.36M derived: sum of 2 quarters · filed 2026-02-26 | $9.41M derived: sum of 3 quarters · filed 2026-02-26 | $11.98M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.80M 10-Q · filed 2025-11-05 | $7.85M derived: sum of 2 quarters · filed 2025-11-05 | $10.42M 10-Q · filed 2025-11-05 | $13.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $6.05M 10-Q · filed 2025-08-06 | $8.62M 10-Q · filed 2025-08-06 | $11.29M derived: sum of 3 quarters · filed 2026-02-26 | $14.11M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.57M 10-Q · filed 2025-05-08 | $5.24M derived: sum of 2 quarters · filed 2026-02-26 | $8.06M derived: sum of 3 quarters · filed 2026-02-26 | |
| 2023-12-31 | $2.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.49M derived: sum of 2 quarters · filed 2026-02-26 | $15.15M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $2.81M 10-Q · filed 2024-11-07 | $12.47M 10-Q · filed 2024-11-07 | ||
| 2022-12-31 | $15.01M 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |